{"analyses":[{"ciLowerLimit":"0.867","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.497","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8253","paramType":"Hazard Ratio (HR)","paramValue":"1.14","statisticalComment":"1-sided","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.672","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.179","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2082","paramType":"Hazard Ratio (HR)","paramValue":"0.89","statisticalComment":"1-sided","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.9","upperLimit":"14.1","value":"11.8"},{"groupId":"OG001","lowerLimit":"12.7","upperLimit":"18.7","value":"15.7"},{"groupId":"OG002","lowerLimit":"11.8","upperLimit":"15.5","value":"13.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"188"},{"groupId":"OG002","value":"190"}],"units":"Participants"}],"description":"OS is defined as the time from the date of randomization to the date of death due to any cause. OS time was summarized by treatment arm using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"paramType":"MEDIAN","populationDescription":"The primary analyses of OS were performed based on the Full Analysis Set (FAS). The FAS included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From randomization until the date of first documented progression or date of deaths from any cause, whichever came first, assessed up to 30 months (based on cutoff date: 19 September 2018).","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}